HighCape Capital, L.P.
Known title: DirectorCIK: 0001826279
HighCape Capital, L.P.'s purchase track record
How the stock did after each of HighCape Capital, L.P.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since December 8, 2021
Stock higher 6 months later
33%
3 months: 33%
Median 6-month return
-27.9%
3 months: -10.6%
Beat the S&P 500
33%
median -33.5% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/3/2025 | ELUT | $2.10M | -31.2% | -27.9% | +5.6% |
| 12/5/2022 | ELUT | $3.49M | +17.3% | -30.9% | +6.9% |
| 12/8/2021 | ELUT | $1.75M | -10.6% | +11.5% | -12.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ELUT | ▲ Buy | Open Market | 420,000 | $1.1M | 2/3/2025 | View on chart |
| ELUT | ▲ Buy | Open Market | 420,000 | $1.1M | 2/3/2025 | View on chart |
| ELUT | ▼ Sell | Other | 2,101,577 | $3.0M | 7/30/2024 | View on chart |
| ELUT | ▼ Sell | Other | 1,436,077 | — | 12/28/2023 | View on chart |
| ELUT | ▲ Buy | Open Market | 735,000 | $3.5M | 12/5/2022 | View on chart |
| ELUT | ▲ Buy | Open Market | 58,962 | $250K | 12/8/2021 | View on chart |
| ELUT | ▲ Buy | Open Market | 353,773 | $1.5M | 12/8/2021 | View on chart |
| ELUT | ▲ Buy | Open Market | 2,837,128 | — | 9/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Elutia Secures $8M from Boston Scientific, Funds Through 2029
Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.
Elutia Secures $8M from Boston Scientific, Funds Through 2029. Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.